Zydus Cadila gets USFDA nod for Mesalamine ER capsules

It is indicated for the maintenance of remission of ulcerative colitis in adults.

99
USFDA
Picture: Pixabay

Last Updated on August 18, 2021 by The Health Master

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market mesalamine extended-release capsules in the strength of 0.375 g.

Mesalamine extended-release capsules are indicated for the maintenance of remission of ulcerative colitis in adults.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion

Alembic gets USFDA nod for Clomipramine HCL Capsules

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

42 FDA Officers honoured on 15th August 2021: Independence Day

Govt removes DPCO 2013’s this clause on ceiling price revision

Latest Notifications regarding Pharmaceuticals

Ceiling Prices of drugs: Govt takes measures to mandatorily revise …

First Nasal Vaccine gets nod for Phase 2 trial: Bharat Biotech

Green Ministry drops Antibiotic effluent limits from new rules

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner